Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulablity and High Risk of VTE. The Roadmap Study

被引：0
|
作者：
Fotiou, Despina [1 ]
Gerotziafas, Grigorios [2 ]
Zagouri, Flora [3 ]
Sergentanis, Theodoros [3 ]
机构：
[1] Alexandra Hosp, Oncol & Hematol Dept, Athens, Greece
[2] Tenon Univ Hosp, Fac Med Pierre Marie Curie, Serv Hematol Biol, Paris, France
[3] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.174
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-172
引用
收藏
页码：E97 / E97
页数：1
相关论文
共 50 条
  • [41] High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
    Dong, Mengmeng
    Zhang, Jinna
    Chen, Qingxiao
    He, Donghua
    Yan, Haimeng
    Zheng, Gaofeng
    Han, Xiaoyan
    He, Jingsong
    Cai, Zhen
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] High Serum IL-17A Is Associated with Bone Destruction in Newly Diagnosed Multiple Myeloma Patients
    Dong, Mengmeng
    Zhang, Jinna
    Chen, Qingxiao
    He, Honghua
    Yan, Haimeng
    Zheng, Gaofeng
    Han, Xiaoyan
    Huang, He
    He, Jingsong
    Cai, Zhen
    BLOOD, 2022, 140 : 7243 - 7243
  • [43] Overexpression of Integrin ß7 in Newly Diagnosed Multiple Myeloma with High Risk Cytogenetic Abnormality and Poorer Prognosis
    Zheng, Dong
    Wan, Wenli
    Zhu, Mingxia
    Jing, Hongmei
    BLOOD, 2023, 142
  • [44] High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma
    Shan, Xinhe
    Long, Qi
    Garfall, Alfred L.
    Susanibar-Adaniya, Sandra P.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [45] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Korde, Neha
    Derkach, Andriy
    Hultcrantz, Malin
    Maclachlan, Kylee H.
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Lesokhin, Alexander
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Hofmeister, Craig C.
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Usmani, Saad Z.
    Lonial, Sagar
    Joseph, Nisha S.
    BLOOD, 2023, 142
  • [46] Optimising bortezomib in newly diagnosed multiple myeloma
    Rajkumar, S. Vincent
    LANCET ONCOLOGY, 2010, 11 (10): : 909 - 910
  • [47] The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID)
    Li, Ang
    Wu, Qian V.
    Warnick, Greg
    Zakai, Neil A.
    Libby, Edward N., III
    Garcia, David A.
    Lyman, Gary H.
    BLOOD, 2018, 132
  • [48] Cytogenetics in newly diagnosed multiple myeloma.
    Testoni, N
    Ruggeri, D
    Tosi, P
    Carboni, C
    Iacurti, E
    Martinelli, G
    Ronconi, S
    Cavo, M
    Tura, S
    BLOOD, 1999, 94 (10) : 306B - 306B
  • [49] Oprozomib in patients with newly diagnosed multiple myeloma
    Hari, Parameswaran
    Matous, Jeffrey V.
    Voorhees, Peter M.
    Shain, Kenneth H.
    Obreja, Mihaela
    Frye, John
    Fujii, Hisaki
    Jakubowiak, Andrzej J.
    Rossi, Davide
    Sonneveld, Pieter
    BLOOD CANCER JOURNAL, 2019, 9 (9)
  • [50] NEW TREATMENTS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
    Terpos, Evangelos
    LEUKEMIA RESEARCH, 2016, 49 : S15 - S15
12345